Less than one in 10 individuals eligible to benefit from weight-loss injections such as Wegovy have access to them, caution the global health agency as it publishes its first guidance on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for broader and more equitable access to this class of drugs.
Per projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"The latest guidance acknowledges that obesity is a long-term condition that can be treated with thorough and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major obstacles to widespread access to the jabs that can help people shift considerable body mass, explains the agency.
GLP-1 Therapy Shortage
Even in the current most favorable outlook, the production of GLP-1 therapies would only suffice for about 100 million people – under 10% of eligible patients, per the health organization.
The guideline urges countries and companies to increase access, through strategies including patent sharing.
The intellectual property rights on the active ingredient – the core ingredient of a leading brand – is due to expire in several nations in 2026.
The Way Weight-Loss Drugs Function
GLP-1 drugs mimick a natural hormone to delay gastric emptying, reduce hunger and enhance the sense of being full so users consume fewer calories.
Patients usually begin shedding pounds after several weeks of beginning the regular doses.
Evidence points to people may see weight return after a year of stopping the treatment, as their normal food cravings resume.
To be overweight or obese raises your chance for contracting diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns individuals in every country and was responsible for millions of fatalities worldwide in 2024, according to the WHO.
